Investor Presentaiton
Investor Presentation
First six months of 2018
Slide 12
Oral semaglutide demonstrated a consistent reduction in
HbA1c and body weight in the completed PIONEER trials
In completed PIONEER trials, oral semaglutide
lowered HbA1c by 1.1-1.5%-points by end of trial¹
Mean change in HbA1c (%-points)
0.0%
-0.5%
-1.0%
PIONEER 1 PIONEER 2 PIONEER 3 PIONEER 4 PIONEER 7
TILIT
In completed PIONEER trials, oral semaglutide
lowered body weight by ~3-5 kg by end of trial¹
Mean change in weight (kg)
0.0
-1.0
-2.0
-3.0
PIONEER 1 PIONEER 2 PIONEER 3 PIONEER 4 PIONEER 7
-1.1%*
-1.5%
-1.3%*
-1.2%*
-4.0
-3.5*
-1.5%*
-1.4%*
-4.1*
-5.0
-4.7*
-2.0%
-6.0
-5.0*
-2.9*
1 Hypothetical estimand, Mixed Model for Repeated Measurement (MMRM)
* Statistically significant vs comparator (PIONEER 1 vs placebo; PIONEER 2 vs empagliflozin 25 mg;
PIONEER 3 vs sitagliptin 100 mg; PIONEER 4 vs Victoza® 1.8 mg; PIONEER 7 vs sitagliptin 100 mg)
Note: results shown are: PIONEER 1 for 26 weeks with 14 mg oral semaglutide, PIONEER 2 and 4 for 52
weeks with 14 mg oral semaglutide; PIONEER 3 for 78 weeks with 14 mg oral semaglutide; PIONEER 7
for 52 weeks with a mixed dose
novo nordiskView entire presentation